U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07948447) titled 'A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants' on Nov. 10.
Brief Summary: NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
IBD (Inflammatory Bowel Disease)
Healthy Adult Participants
Intervention:
DRUG: NEO-1306
NEO-13...